SAN DIEGO, July 9, 2013 /PRNewswire/ -- Organovo
Holdings, Inc. (OTCQX: ONVO), a biotechnology company focused
on delivering breakthrough three-dimensional (3D) bioprinting
technology, is pleased to announce that its common shares have been
approved to list on the NYSE MKT and will begin trading on the New
York Stock Exchange on July 11,
2013. The Company will continue to trade under the symbol
"ONVO" but will withdraw its shares from listing on the OTC QX
concurrent with listing its shares on the NYSE MKT, the premier US
equities market for listing and trading of small growth
companies.
"Trading on the New York Stock Exchange is an important
milestone for Organovo and will be valuable to our business and
shareholders. Our decision to move to the NYSE MKT was based on a
firm belief that the exchange offers the best set of conditions for
Organovo's success, and thus the best opportunity to add value for
our shareholders," said Keith Murphy, President and CEO of
Organovo Holdings, Inc.. "We found NYSE to have made an
unparalleled commitment to providing a fertile platform for growth
to early stage biotechnology companies, and we look forward to a
great future on the exchange."
NYSE MKT is a fully integrated trading venue within the NYSE
Euronext community and leverages the NYSE's advanced and innovative
market model to offer a premier venue for listing and trading the
stocks of small companies. The venue utilizes the trading,
connectivity and routing technologies of the NYSE platform and
offers superior price discovery, superior liquidity and reduced
trading volatility. Listed companies benefit from
issuer-selected Designated Market Makers (DMM) that utilize
world-class NYSE trading systems to discover and improve prices,
dampen volatility, add liquidity and enhance value. In
addition, NYSE MKT-listed companies gain access to the brand
visibility and are eligible for the issuer services enjoyed by the
NYSE Euronext community.
"We welcome Organovo to the NYSE MKT family of listed
companies," said Scott Cutler,
Executive Vice President, Global Listings at NYSE Euronext.
"Organovo will be joining other growth oriented companies in the
U.S. taking advantage of the NYSE's advanced and innovative market
model to offer a premier value for listing and trading their
stocks."
About Organovo Holdings,
Inc.
Organovo designs and creates functional,
three-dimensional human tissues for medical research and
therapeutic applications. The Company is collaborating with
pharmaceutical and academic partners to develop human biological
disease models in three dimensions. These 3D human tissues have the
potential to accelerate the drug discovery process, enabling
treatments to be developed faster and at lower cost. In addition to
numerous scientific publications, our technology has been featured
in The Wall Street Journal, Time Magazine, The Economist,
and numerous others. Organovo is changing the shape of
medical research and practice. Learn more
at www.organovo.com.
Safe Harbor Statement
Any statements contained in this
press release that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Any forward-looking
statements contained herein are based on current expectations, but
are subject to a number of risks and uncertainties. The factors
that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the Company's ability to develop, market
and sell products based on its technology; the expected benefits
and efficacy of the Company's products and technology; the
availability of substantial additional funding for the Company to
continue its operations and to conduct research and development,
clinical studies and future product commercialization; and the
Company's business, research, product development, regulatory
approval, marketing and distribution plans and strategies. These
and other factors are identified and described in more detail in
our filings with the SEC, including our transition report on
Form 10-KT filed with the SEC on May 24, 2013. You
should not place undue reliance on these forward-looking
statements, which speak only as of the date that they were made.
These cautionary statements should be considered with any written
or oral forward-looking statements that we may issue in the future.
Except as required by applicable law, including the securities laws
of the United States, we do
not intend to update any of the forward-looking statements to
conform these statements to reflect actual results, later events or
circumstances or to reflect the occurrence of unanticipated
events.
SOURCE Organovo Holdings, Inc.
